<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36457099</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Identification of a neutralizing linear epitope within the VP1 protein of coxsackievirus A10.</ArticleTitle><Pagination><StartPage>203</StartPage><MedlinePgn>203</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">203</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-022-01939-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Coxsackievirus A10 (CV-A10) is a leading cause of hand, foot, and mouth disease (HFMD). It is necessary to identify neutralizing epitopes to investigate and develop an epitope-based vaccine against CV-A10. The viral protein VP1 is the immunodominant capsid protein and contains the critical neutralizing epitope. However, neutralizing epitopes within VP1 protein of CV-A10 have not been well characterized.</AbstractText><AbstractText Label="METHODS">Bioinformatics techniques were applied to predict linear epitopes on the CV-A10 VP1 protein. The advanced structural features of epitopes were analyzed by three-dimensional (3D) modeling. The anticipated epitope peptides were synthesized and used to immunize mice as antigens. ELISA and micro-neutralization assay were used to determine the specific IgG antibody and neutralizing antibody titers. The protective efficacy of the epitope peptides in vivo was evaluated using a passive immunization/challenge assay.</AbstractText><AbstractText Label="RESULTS">Three linear epitopes (EP3, EP4, and EP5) were predicted on CV-A10 VP1, all spatially exposed on the capsid surface, and exhibited adequate immunogenicity. However, only EP4, corresponding to residues 162-176 of VP1, demonstrated potent neutralization against CV-A10. To determine the neutralizing capacity of EP4 further, EP4 double-peptide was synthesized and injected into mice. The mean neutralizing antibody titer of the anti-EP4 double-peptide sera was 1:50.79, which provided 40% protection against lethal infection with CV-A10 in neonatal mice. In addition, sequence and advanced structural analysis revealed that EP4 was highly conserved among representative strains of CV-A10 and localized in the EF loop region of VP1, like EV-A71 SP55 or CV-A16 PEP55.</AbstractText><AbstractText Label="CONCLUSIONS">These data demonstrate that EP4 is a specific linear neutralizing epitope on CV-A10 VP1. Its protective efficacy can be enhanced by increasing its copy number, which will be the foundation for developing a CV-A10 epitope-based vaccine.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhu</LastName><ForeName>Hanyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Medical Biotechnology and Translational Medicine (Guilin Medical University), Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Medical Biotechnology and Translational Medicine (Guilin Medical University), Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yunyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Huanying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongbo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China. hbliu@glmc.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, Guilin, Guangxi, China. hbliu@glmc.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Medical Biotechnology and Translational Medicine (Guilin Medical University), Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China. hbliu@glmc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiliang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>College of Intelligent Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi, China. aqua02@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Medical Biotechnology and Translational Medicine (Guilin Medical University), Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China. aqua02@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="Y">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A10</Keyword><Keyword MajorTopicYN="N">Epitope</Keyword><Keyword MajorTopicYN="N">Neutralization</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>0</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36457099</ArticleId><ArticleId IdType="pmc">PMC9714398</ArticleId><ArticleId IdType="doi">10.1186/s12985-022-01939-3</ArticleId><ArticleId IdType="pii">10.1186/s12985-022-01939-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li K, Dong F, Cui B, Cui L, Liu P, Ma C, Zheng H, Wu X, Liang Z. Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10. Hum Vaccin Immunother. 2020;16(6):1434–40. doi: 10.1080/21645515.2019.1691404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1691404</ArticleId><ArticleId IdType="pmc">PMC7482785</ArticleId><ArticleId IdType="pubmed">31851566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Sun Y, Fan J, Zhu B, Cao L, Gao Q, Zhang Y, Liu H, Rao Z, Wang X. Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating. Nat Commun. 2018;9(1):4985. doi: 10.1038/s41467-018-07531-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07531-0</ArticleId><ArticleId IdType="pmc">PMC6255764</ArticleId><ArticleId IdType="pubmed">30478256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Gao F, Mao Q, Sun S, Wu X, Liu S, Yang X, Liang Z. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev Anti Infect Ther. 2019;17(4):233–42. doi: 10.1080/14787210.2019.1585242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2019.1585242</ArticleId><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Li J, Carr MJ, Zhuang D, Wang J, Zhang Y, Ding S, Tong Y, Li D, Shi W. Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of Coxsackievirus A10 infection. J Virol. 2017;91(13):e00333–17. doi: 10.1128/JVI.00333-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00333-17</ArticleId><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W, Xiong P, Zhang X, Liu Z, Chen J, Zhou Y, Ye X, Zhang C. Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice. Antiviral Res. 2019;164:139–46. doi: 10.1016/j.antiviral.2019.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.02.016</ArticleId><ArticleId IdType="pubmed">30817941</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, Li Y, Liu G, Jiang Y, Shen S, Bi R, Huang H, Cheng T, Wang C, Wei W. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nat Commun. 2019;10(1):4066. doi: 10.1038/s41467-019-12040-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12040-9</ArticleId><ArticleId IdType="pmc">PMC6731315</ArticleId><ArticleId IdType="pubmed">31492846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhou D, Ni T, Karia D, Kotecha A, Wang X, Rao Z, Jones EY, Fry EE, Ren J, Stuart DI. Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. Nat Commun. 2020;11(1):38. doi: 10.1038/s41467-019-13936-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13936-2</ArticleId><ArticleId IdType="pmc">PMC6946704</ArticleId><ArticleId IdType="pubmed">31911601</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccin. 2018;17(9):819–31. doi: 10.1080/14760584.2018.1510326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125(1):61–8. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Ang RX, Alonso S, Chow VT, Quak SH, Poh CL. Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in Western blots. Clin Microbiol Infect. 2008;14(3):286–8. doi: 10.1111/j.1469-0691.2007.01904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2007.01904</ArticleId><ArticleId IdType="pubmed">18076666</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362–72. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Poh CL, Fecondo J, Pourianfar H, Shaw J, Grollo L. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. Vaccine. 2012;30(49):7105–10. doi: 10.1016/j.vaccine.2012.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Syed SF, Zhou EM. Antigenic properties of avian hepatitis E virus capsid protein. Vet Microbiol. 2015;180(1–2):10–14. doi: 10.1016/j.vetmic.2015.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2015.08.016</ArticleId><ArticleId IdType="pubmed">26340899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT, Kwang J. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J. 2012;9:55. doi: 10.1186/1743-422X-9-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-55</ArticleId><ArticleId IdType="pmc">PMC3307493</ArticleId><ArticleId IdType="pubmed">22361222</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Zhang Y, Ji T, Gu X, Yang Q, Zhu S, Xu W, Xu Y, Shi Y, Huang X, Li Q, Deng H, Wang X, Yan D, Yu W, Wang S, Yu D, Xu W. Persistent circulation of Coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015. Sci Rep. 2017;7(1):5491. doi: 10.1038/s41598-017-05618-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-05618-0</ArticleId><ArticleId IdType="pmc">PMC5511160</ArticleId><ArticleId IdType="pubmed">28710474</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Kanwar M, Santra D, Maiti S. Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike. Transl Med Commun. 2022;7(1):2. doi: 10.1186/s41231-022-00109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41231-022-00109-5</ArticleId><ArticleId IdType="pmc">PMC8814807</ArticleId><ArticleId IdType="pubmed">35136839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Huang H, Xu L, Lou C, Pan M. Screening and identification of linear B cell epitopes within the nonstructural proteins of enterovirus 71. Viral Immunol. 2019;32(2):84–88. doi: 10.1089/vim.2018.0125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2018.0125</ArticleId><ArticleId IdType="pubmed">30523737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HB, Yang GF, Liang SJ, Lin J. Bioinformatic analysis of non-VP1 capsid protein of coxsackievirus A6. J Huazhong Univ Sci Technol Med Sci. 2016;36(4):607–13. doi: 10.1007/s11596-016-1633-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-016-1633-4</ArticleId><ArticleId IdType="pubmed">27465341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad I, Ali SS, Zafar B, Hashmi HF, Shah I, Khan S, Suleman M, Khan M, Ullah S, Ali S, Khan J, Ali M, Khan A, Wei DQ. Development of multi-epitope subunit vaccine for protection against the norovirus' infections based on computational vaccinology. J Biomol Struct Dyn. 2022;40(7):3098–109. doi: 10.1080/07391102.2020.1845799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1845799</ArticleId><ArticleId IdType="pubmed">33170093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HZ, Tang LL, Yu XL, Zhou J, Chang YF, Wu X. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. Infect Dis Poverty. 2020;9(1):88. doi: 10.1186/s40249-020-00713-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00713-3</ArticleId><ArticleId IdType="pmc">PMC7395940</ArticleId><ArticleId IdType="pubmed">32741372</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmus LM, Guan J, Wu T, Farenc C, Sng XYX, Zareie P, Nguyen A, Nguyen AT, Tscharke DC, Thomas PG, Rossjohn J, Gras S, Croft NP, Purcell AW, La Gruta NL. Overlapping peptides elicit distinct CD8(+) T cell responses following influenza A virus infection. J Immunol. 2020;205(7):1731–42. doi: 10.4049/jimmunol.2000689.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000689</ArticleId><ArticleId IdType="pmc">PMC7511415</ArticleId><ArticleId IdType="pubmed">32868409</ArticleId></ArticleIdList></Reference><Reference><Citation>Khudyakov YE, Lopareva EN, Jue DL, Fang S, Spelbring J, Krawczynski K, Margolis HS, Fields HA. Antigenic epitopes of the hepatitis A virus polyprotein. Virology. 1999;260(2):260–72. doi: 10.1006/viro.1999.9813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1999.9813</ArticleId><ArticleId IdType="pubmed">10417261</ArticleId></ArticleIdList></Reference><Reference><Citation>Olvera A, Noguera-Julian M, Kilpelainen A, Romero-Martin L, Prado JG, Brander C. SARS-CoV-2 consensus-sequence and matching overlapping peptides design for COVID19 immune studies and vaccine development. Vaccines (Basel) 2020;8(3):444. doi: 10.3390/vaccines8030444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030444</ArticleId><ArticleId IdType="pmc">PMC7565482</ArticleId><ArticleId IdType="pubmed">32781672</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan DW, Minneci F, Nugent TC, Bryson K, Jones DT. Scalable web services for the PSIPRED Protein Analysis Workbench. Nucl Acids Res. 2013;41(Web Server issue):W349–57. doi: 10.1093/nar/gkt381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt381</ArticleId><ArticleId IdType="pmc">PMC3692098</ArticleId><ArticleId IdType="pubmed">23748958</ArticleId></ArticleIdList></Reference><Reference><Citation>Plasterer TN. PROTEAN. Protein sequence analysis and prediction. Mol Biotechnol. 2000;16(2):117–25. doi: 10.1385/MB:16:2:117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MB:16:2:117</ArticleId><ArticleId IdType="pubmed">11131972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8(2):e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Zhao H, Yang L, Hou W, Xu L, Wu Y, Wang W, Chen C, Wan J, Ye X, Liang Z, Mao Q, Cheng T, Xia N. A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Res. 2017;144:247–55. doi: 10.1016/j.antiviral.2017.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.06.008</ArticleId><ArticleId IdType="pubmed">28625478</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967–76. doi: 10.1128/JVI.00902-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Dan H, Zhao X, Chen H, Chen Y, Zhang N, Mo Z, Liu H. Construction and characterization of an infectious cDNA clone of coxsackievirus A 10. Virol J. 2019;16(1):98. doi: 10.1186/s12985-019-1201-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1201-1</ArticleId><ArticleId IdType="pmc">PMC6685229</ArticleId><ArticleId IdType="pubmed">31387601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, Ye X, Liu Q, Zhou D, Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94. doi: 10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Z, Su R, Wang W, Liang Y, Zeng X, Shereen MA, Bashir N, Zhang Q, Zhao L, Wu K, Liu Y, Wu J. EV71 infection induces neurodegeneration via activating TLR7 signaling and IL-6 production. PLOS Pathog. 2019;15(11):e1008142. doi: 10.1371/journal.ppat.1008142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008142</ArticleId><ArticleId IdType="pmc">PMC6932824</ArticleId><ArticleId IdType="pubmed">31730654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, Sai IH, Chang JY, Lin SC, Sia C, Hsiao CH, Chou AH, Chong P. Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods. 2011;176(1–2):60–8. doi: 10.1016/j.jviromet.2011.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.06.001</ArticleId><ArticleId IdType="pubmed">21704080</ArticleId></ArticleIdList></Reference><Reference><Citation>He SZ, Chen MY, Xu XR, Yan Q, Niu JJ, Wu WH, Su XS, Ge SX, Zhang SY, Xia NS. Epidemics and aetiology of hand, foot and mouth disease in Xiamen, China, from 2008 to 2015. Epidemiol Infect. 2017;145(9):1865–1874. doi: 10.1017/S0950268817000309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268817000309</ArticleId><ArticleId IdType="pmc">PMC9203317</ArticleId><ArticleId IdType="pubmed">28367766</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez G, Carr MJ, Kobayashi M, Hanaoka N, Fujimoto T. Enterovirus-associated hand-foot and mouth disease and neurological complications in Japan and the rest of the world. Int J Mol Sci. 2019;20(20):5201. doi: 10.3390/ijms20205201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205201</ArticleId><ArticleId IdType="pmc">PMC6834195</ArticleId><ArticleId IdType="pubmed">31635198</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Strating JRPM, van Kuppeveld FJM. T The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368–81. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer A, Van Der Sanden S, Snijders BE, Jaramillo-Gutierrez G, Bont L, Van Der Ent CK, Overduin P, Jenny SL, Jusic E, van der Avoort HG, Smith GJ, Donker GA, Koopmans MP. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology. 2012;423(1):49–57. doi: 10.1016/j.virol.2011.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.11.021</ArticleId><ArticleId IdType="pubmed">22177700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho BC, Yang PC, Yu SL. MicroRNA and pathogenesis of enterovirus infection. Viruses. 2016;8(1):11. doi: 10.3390/v8010011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8010011</ArticleId><ArticleId IdType="pmc">PMC4728571</ArticleId><ArticleId IdType="pubmed">26751468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>